Xenon Pharmaceuticals IncNASDAQ:XENE
- LAST PRICE38.3700
- TODAY'S CHANGE (%)-0.0900 (-0.2340%)
- Bid / Lots37.2900/ 1
- Ask / Lots40.4800/ 1
- Open / Previous Close38.3400 / 38.4600
- Day Range
- 52 Week Range
- Volume193,372
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | XENE |
|---|---|---|
| 09:32 ET | 1756 | 38.34 |
| 09:34 ET | 900 | 38.475 |
| 09:36 ET | 492 | 38.21 |
| 09:38 ET | 10400 | 38.35 |
| 09:39 ET | 5253 | 39.02 |
| 09:41 ET | 400 | 38.47 |
| 09:48 ET | 4311 | 39.11 |
| 09:50 ET | 300 | 38.8 |
| 09:56 ET | 100 | 38.705 |
| 09:59 ET | 200 | 38.655 |
| 10:06 ET | 100 | 38.67 |
| 10:08 ET | 836 | 38.655 |
| 10:10 ET | 100 | 38.635 |
| 10:12 ET | 100 | 38.51 |
| 10:14 ET | 100 | 38.65 |
| 10:15 ET | 500 | 38.65 |
| 10:17 ET | 100 | 38.57 |
| 10:21 ET | 100 | 38.585 |
| 10:24 ET | 1606 | 38.8 |
| 10:30 ET | 100 | 38.78 |
| 10:32 ET | 100 | 38.8 |
| 10:33 ET | 100 | 38.82 |
| 10:35 ET | 600 | 38.88 |
| 10:39 ET | 100 | 38.945 |
| 10:48 ET | 786 | 39.08 |
| 10:51 ET | 100 | 39.14 |
| 10:53 ET | 100 | 39.05 |
| 11:02 ET | 102 | 39.03 |
| 11:06 ET | 522 | 39.1875 |
| 11:13 ET | 100 | 39.23 |
| 11:15 ET | 100 | 39.21 |
| 11:20 ET | 100 | 39.18 |
| 11:24 ET | 1200 | 39.06 |
| 11:26 ET | 800 | 39.0525 |
| 11:27 ET | 100 | 38.98 |
| 11:29 ET | 200 | 38.94 |
| 11:31 ET | 100 | 39.01 |
| 11:33 ET | 521 | 39.06 |
| 11:36 ET | 200 | 38.96 |
| 11:38 ET | 310 | 38.915 |
| 11:45 ET | 450 | 38.6594 |
| 11:54 ET | 1000 | 38.6 |
| 11:56 ET | 100 | 38.54 |
| 12:07 ET | 2100 | 38.685 |
| 12:12 ET | 300 | 38.63 |
| 12:14 ET | 100 | 38.59 |
| 12:16 ET | 200 | 38.56 |
| 12:18 ET | 435 | 38.625 |
| 12:21 ET | 250 | 38.63 |
| 12:23 ET | 1100 | 38.59 |
| 12:25 ET | 700 | 38.53 |
| 12:27 ET | 100 | 38.51 |
| 12:32 ET | 700 | 38.5 |
| 12:34 ET | 100 | 38.6 |
| 12:39 ET | 832 | 38.605 |
| 12:41 ET | 421 | 38.53 |
| 12:43 ET | 100 | 38.5775 |
| 12:45 ET | 3162 | 38.74 |
| 01:06 ET | 400 | 38.51 |
| 01:10 ET | 400 | 38.49 |
| 01:12 ET | 300 | 38.47 |
| 01:15 ET | 427 | 38.54 |
| 01:19 ET | 200 | 38.555 |
| 01:32 ET | 100 | 38.535 |
| 01:33 ET | 200 | 38.495 |
| 01:48 ET | 100 | 38.47 |
| 01:50 ET | 300 | 38.45 |
| 01:51 ET | 100 | 38.31 |
| 01:57 ET | 419 | 38.41 |
| 02:00 ET | 100 | 38.4 |
| 02:02 ET | 300 | 38.33 |
| 02:18 ET | 100 | 38.24 |
| 02:22 ET | 100 | 38.33 |
| 02:31 ET | 700 | 38.2 |
| 02:33 ET | 100 | 38.15 |
| 02:36 ET | 200 | 38.11 |
| 02:40 ET | 7586 | 38.25 |
| 02:42 ET | 100 | 38.25 |
| 02:44 ET | 100 | 38.255 |
| 02:45 ET | 1198 | 38.315 |
| 02:47 ET | 100 | 38.38 |
| 02:49 ET | 2143 | 38.41 |
| 02:51 ET | 700 | 38.52 |
| 02:54 ET | 3190 | 38.57 |
| 02:56 ET | 600 | 38.65 |
| 02:58 ET | 1713 | 38.8263 |
| 03:00 ET | 744 | 38.77 |
| 03:02 ET | 300 | 38.85 |
| 03:03 ET | 675 | 38.76 |
| 03:16 ET | 997 | 38.59 |
| 03:18 ET | 501 | 38.54 |
| 03:20 ET | 1037 | 38.45 |
| 03:23 ET | 1055 | 38.34 |
| 03:25 ET | 700 | 38.3 |
| 03:30 ET | 200 | 38.35 |
| 03:32 ET | 100 | 38.375 |
| 03:38 ET | 100 | 38.39 |
| 03:39 ET | 3682 | 38.545 |
| 03:41 ET | 2219 | 38.48 |
| 03:48 ET | 2796 | 38.525 |
| 03:50 ET | 2800 | 38.385 |
| 03:52 ET | 2894 | 38.35 |
| 03:54 ET | 3370 | 38.355 |
| 03:56 ET | 2770 | 38.28 |
| 03:57 ET | 4070 | 38.3 |
| 03:59 ET | 30060 | 38.37 |
May 10, 2024
DJ Xenon Pharmaceuticals Is Maintained at Buy by Needham, from 6:12PM ET on Friday May 10, 2024 by Dow Jones
6:12PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Buy by Citigroup, from 5:48PM ET on Friday May 10, 2024 by Dow Jones
5:48PM ET on Friday May 10, 2024 by Dow JonesDJ Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush, from 9:30AM ET on Friday May 10, 2024 by Dow Jones
9:30AM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update, from 4:01PM ET on Thursday May 09, 2024 by Dow Jones
4:01PM ET on Thursday May 09, 2024 by Dow Jones*DJ Xenon Pharmaceuticals 1Q Loss/Shr 62c >XENE, from 4:01PM ET on Thursday May 09, 2024 by Dow Jones
4:01PM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Xenon Pharmaceuticals Inc | 2.9B | -14.1x | --- |
Apogee Therapeutics Inc | 2.8B | -23.5x | --- |
Iovance Biotherapeutics Inc | 2.8B | -5.5x | --- |
Dyne Therapeutics Inc | 3.0B | -7.9x | --- |
IDEAYA Biosciences Inc | 2.9B | -18.9x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Company Information
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Contact Information
- Headquarters
- 3650 Gilmore WayVANCOUVER, BC, Canada V5G 4W8
- Phone
- 604-484-3300
- Fax
- 604-484-3450
Executives
- Chairman of the Board
- Simon Pimstone
- President, Chief Executive Officer, Director
- Ian Mortimer
- Chief Financial Officer
- Sherry Aulin
- Executive Vice President - Drug Discovery
- James Empfield
- Executive Vice President - Strategy and Innovation
- Robin Sherrington
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.9B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 75.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.23 |
EPS | $-2.71 |
Book Value | $12.31 |
P/E Ratio | -14.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
